Gallagher Kathleen C, Geromes Ariana B, Stokes John, Reddy India A, Lewis James S, Baregamian Naira
Division of Surgical Oncology and Endocrine Surgery, Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee 37232.
Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232.
J Endocr Soc. 2018 Jan 3;2(2):112-116. doi: 10.1210/js.2017-00445. eCollection 2018 Feb 1.
Primary amyloidosis (PA) is a protein deposition disorder that presents with localized or multisystemic disease. The incidence is low in the general public, ranging from three to eight cases per million, and with nonspecific presenting symptoms typically occurring later in life. Due to late presentation, substantial and irreversible damage has usually already occurred by the time of the diagnosis. However, if inadvertent diagnosis occurs before irreversible damage has taken place, as it did in the following case, some patients may benefit from the disease-arresting treatment. A 70-year-old female with a history of obstructive sleep apnea, hypertension, and arthritis presented with worsening dysphagia and biochemically confirmed primary hyperparathyroidism (PHPT). Further workup demonstrated multinodular goiter with compressive symptoms and substernal extension, osteopenia, and discrepant parathyroid localization on imaging. Intraoperatively, markedly difficult dissection and obliteration of tissue planes were encountered. Extensive, diffuse amyloid deposition in both the normal and pathologic parathyroid glands and thyroid tissue on surgical pathology leads to subsequent fibril typing by mass spectrometry and leads to the diagnostic of primary amyloid light-chain (AL) amyloidosis (PA; light chains). Subsequent workup for the underlying cause of the amyloid deposition revealed an immunoglobulin A monoclonal gammopathy of unknown significance. The surgical treatment of PHPT and compressive thyroid nodule unmasked an undiagnosed PA, allowing for early workup and monitoring of the progression of amyloidosis. The temporal comorbidity of PHPT and PA raises an interesting and, as yet, unanswered question regarding the pathophysiologic association between the two conditions.
原发性淀粉样变性(PA)是一种蛋白质沉积性疾病,可表现为局限性或多系统疾病。在普通人群中发病率较低,每百万人口中约有3至8例,且非特异性症状通常在晚年出现。由于就诊较晚,在诊断时通常已经发生了严重且不可逆的损害。然而,如果在不可逆损害发生之前偶然做出诊断,如下例所示,一些患者可能会从疾病抑制治疗中获益。一名70岁女性,有阻塞性睡眠呼吸暂停、高血压和关节炎病史,出现吞咽困难加重,并经生化检查确诊为原发性甲状旁腺功能亢进症(PHPT)。进一步检查发现多结节性甲状腺肿伴有压迫症状及胸骨后延伸、骨质减少,且影像学检查甲状旁腺定位不一致。术中,遇到了明显困难的组织分离和组织平面消失情况。手术病理显示正常和病变的甲状旁腺及甲状腺组织中均有广泛、弥漫性淀粉样沉积,随后通过质谱进行原纤维分型,诊断为原发性轻链(AL)淀粉样变性(PA;轻链)。对淀粉样沉积的潜在原因进行的后续检查发现了意义未明的免疫球蛋白A单克隆丙种球蛋白病。PHPT和压迫性甲状腺结节的手术治疗揭示了未被诊断的PA,从而能够对淀粉样变性的进展进行早期检查和监测。PHPT和PA的时间上的共病提出了一个有趣但尚未得到解答的问题,即这两种疾病之间的病理生理关联。